19 March, 2008 : Axis-Shield (LSE:ASD, OSE:ASD), the international in-vitro diagnostics (IVD) company, announces that it has received U.S. Food and Drug Administration (FDA) marketing clearance for its novel HbA1c test, formulated to run on the widely placed, high-throughput AxSYM® laboratory analyser from Abbott . The test, which is used to monitor treatment efficacy in patients with diabetes, will now be launched into the important US marketplace. Assay development involved novel Axis-Shield patented technology from pioneering research at its Dundee plant, which has allowed measurement of this important marker on an automated high throughput immunoassay system... Axis-Shield's Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
March
(40)
- Medtronic : Announces Sales Milestone of One Milli...
- AgaMatrix : WaveSense Europe Launches Jazz Glucose...
- Boston Scientific : TAXUS Express Stent Shows Simi...
- SemBioSys : toxicology study for safflower-produce...
- Keryx Biopharmaceuticals : Termination of SUN-MACR...
- Atherotech 's VAP Test Helps Researchers Uncover B...
- Generex Biotechnology : Its Protocol for Metcontr...
- Echo Therapeutics : Positive Results from Symphony...
- Oramed Pharmaceuticals : Phase 2A Trials of Its Or...
- MacroChem, Pexiganan Phase 3 Study Results for Top...
- MannKind : Response to Recent Market Events
- Generex Oral-lyn, another regulatory approval to c...
- Metabolon and EGIR, Partnership to Accelerate Pre-...
- Mercury Therapeutics : series of indirect AMPK act...
- Sirtris' SIRT1 Activators; Patent Covers First NCE...
- DiObex and Camurus , Agreement for the Development...
- Lilly and Transition Therapeutics, Licensing and C...
- Synvista Therapeutics, Newly Published Data Demons...
- PPD, Takeda's NDA Filing of Alogliptin with U.S. F...
- Alizyme's cetilistat Phase III development program...
- Axis-Shield, HbA1c Test on Abbott's AXSYM Analyser
- Marcadia Biotech and Merck, strategic collaboration
- OSI Pharmaceuticals : the Prior Revocation of Its ...
- Hollis-Eden Pharmaceuticals, Positive Preliminary ...
- Diamyd Medical, Authorization to Begin Phase III S...
- Sernova, First Regulatory Step Towards Clinical Tr...
- Cannasat Therapeutics, Update on Patent Applicatio...
- Living Cell Technologies' DiabeCell Clinical Trial...
- Nitric BioTherapeutics, Phase II Clinical Trial fo...
- Oramed Pharmaceuticalsals, Phase 1B Clinical Trial...
- Abbott's FreeStyle Navigator Continuous Glucose Mo...
- Elixir Pharmaceuticals, new data on the role of gh...
- Akesis Pharmaceuticals, First Patient in Phase IIa...
- Oculus Innovative Sciences, Phase II Data with Mic...
- Alkermes, Eli Lilly, Termination of AIR (Inhaled) ...
- PLC Systems' RenalGuard Therapy and RenalGuard Sys...
- Novocell, Successful Use of Stem Cells to Generate...
- Novartis Eucreas combination of Galvus® and metfor...
- Johnson & Johnson Diabetes Institute, New Center T...
- Metabasis Therapeutics, Proof-of-Concept Clinical ...
-
▼
March
(40)